InvestorsHub Logo
Followers 69
Posts 6694
Boards Moderated 0
Alias Born 02/10/2010

Re: ddls post# 266501

Saturday, 05/29/2021 7:44:00 PM

Saturday, May 29, 2021 7:44:00 PM

Post# of 334479
All Straw Man arguments addressed many times on this Board


Investors are waiting for the next Q results, and if they seriously increase sales or not. I'm sure Kelly will "pre announce" if they are good (but how good). Whatever the number some will say it is not good enough

too many shares, too many noteholders, many due in this years second half. BIEL financed Five FDA Clearances with the current debt, they are now monetizing those Clearances

Many pink investors don't think BIEL can sustain sales, I agree. DJO, KT Tape, SAI Brands and their combined 175 years of Medical Device experience disagree with your opinion

Many investors aren't impressed with the volatility (classic pink flipper) and the current management (the family run scam). We all know how this share structure is abused. New management, New BOD, New COB, New OEM Business Plan, New OEM Partners, New CE Certification, New Post-Op Clearance, New Full Body Pain Clearance, a lot of Positive changes and excellent results

The lack of reporting on time (except for Q1) on a consistent basis.
Plus the OTC Yield signs on a consistent basis. Financial Statement was on time, the Atty Letter was late, took OTC Markets 10 days to clear Yield sign after letter submitted.

Many investors see this as a dead sector, which it is. BIEL is too late with too little for the game. LOL, the Global Pain Relief Market was worth 65 Billion in 2020

If BIEL can't even finish in the top 10 at the FDA Opioid Challenge why would the professional investor care about this junk? There were 250 entrants in the Challenge, there was no 'Top 10', there were 2 Grants given out for each of the 4 categories, Pfizer also entered and and received no Grant, none of the Grants were given to OTC products